title: Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells.
abstract: BACKGROUND
  Plasmacytoid dendritic cells (pDCs) play not only a central role in the antiviral immune response in innate host defense, but also a pathogenic role in the development of the autoimmune process by their ability to produce robust amounts of type I interferons (IFNs), through sensing nucleic acids by toll-like receptor (TLR) 7 and 9. Thus, control of dysregulated pDC activation and type I IFN production provide an alternative treatment strategy for autoimmune diseases in which type I IFNs are elevated, such as systemic lupus erythematosus (SLE). Here we focused on IkappaB kinase inhibitor BAY 11-7082 (BAY11) and investigated its immunomodulatory effects in targeting the IFN response on pDCs.
  
  
  METHODS
  We isolated human blood pDCs by flow cytometry and examined the function of BAY11 on pDCs in response to TLR ligands, with regards to pDC activation, such as IFN-alpha production and nuclear translocation of interferon regulatory factor 7 (IRF7) in vitro. Additionally, we cultured healthy peripheral blood mononuclear cells (PBMCs) with serum from SLE patients in the presence or absence of BAY11, and then examined the inhibitory function of BAY11 on SLE serum-induced IFN-alpha production. We also examined its inhibitory effect in vivo using mice pretreated with BAY11 intraperitonealy, followed by intravenous injection of TLR7 ligand poly U.
  
  
  RESULTS
  Here we identified that BAY11 has the ability to inhibit nuclear translocation of IRF7 and IFN-alpha production in human pDCs. BAY11, although showing the ability to also interfere with tumor necrosis factor (TNF)-alpha production, more strongly inhibited IFN-alpha production than TNF-alpha production by pDCs, in response to TLR ligands. We also found that BAY11 inhibited both in vitro IFN-alpha production by human PBMCs induced by the SLE serum and the in vivo serum IFN-alpha level induced by injecting mice with poly U.
  
  
  CONCLUSIONS
  These findings suggest that BAY11 has the therapeutic potential to attenuate the IFN environment by regulating pDC function and provide a novel foundation for the development of an effective immunotherapeutic strategy against autoimmune disorders such as SLE.
authors.affiliation: First Department of Internal Medicine, Kansai Medical University, 10-15, Fumizono, Moriguchi, Osaka, 570-8506, Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Miyamoto
authors.forename: Tomoki
authors.initials: T
authors.lastname: Ito
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Amakawa
authors.forename: Hideki
authors.initials: H
authors.lastname: Amuro
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Katashiba
authors.forename: Makoto
authors.initials: M
authors.lastname: Ogata
authors.forename: Naoko
authors.initials: N
authors.lastname: Murakami
authors.forename: Keiko
authors.initials: K
authors.lastname: Shimamoto
authors.forename: Chihiro
authors.initials: C
authors.lastname: Yamazaki
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Hoshino
authors.forename: Tsuneyasu
authors.initials: T
authors.lastname: Kaisho
authors.forename: Shirou
authors.initials: S
authors.lastname: Fukuhara
mesh_terms: D000328:Adult; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002467:Cell Nucleus / Q000378:metabolism*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D050839:Interferon Regulatory Factor-7 / Q000378:metabolism*; D007370:Interferon Type I / Q000378:metabolism*; D016898:Interferon-alpha / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D009570:Nitriles / Q000494:pharmacology*; D013450:Sulfones / Q000494:pharmacology*
chemical_list: C434003:3-(4-methylphenylsulfonyl)-2-propenenitrile; D050839:Interferon Regulatory Factor-7; D007370:Interferon Type I; D016898:Interferon-alpha; D009570:Nitriles; D013450:Sulfones; D051550:I-kappa B Kinase
references.citation: J Autoimmun. 1998 Oct;11(5):465-70
references.pmid: 9802930
references.citation: J Immunol. 2003 Jul 1;171(1):88-95
references.pmid: 12816986
references.citation: Blood. 2004 Apr 1;103(7):2761-70
references.pmid: 14645003
references.citation: Nat Rev Immunol. 2008 Aug;8(8):594-606
references.pmid: 18641647
references.citation: Immunity. 2006 Sep;25(3):383-92
references.pmid: 16979570
references.citation: Nature. 2006 Apr 13;440(7086):949-53
references.pmid: 16612387
references.citation: J Immunol. 2009 Jun 1;182(11):6824-33
references.pmid: 19454678
references.citation: J Biol Chem. 1997 Aug 22;272(34):21096-103
references.pmid: 9261113
references.citation: Nature. 2007 Oct 4;449(7162):564-9
references.pmid: 17873860
references.citation: Nature. 2008 Mar 20;452(7185):323-8
references.pmid: 18272964
references.citation: Breast Cancer Res Treat. 2007 Apr;102(2):157-72
references.pmid: 17039268
references.citation: J Exp Med. 2005 Mar 21;201(6):915-23
references.pmid: 15767370
references.citation: Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15416-21
references.pmid: 15492225
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3372-7
references.pmid: 15728381
references.citation: J Exp Med. 2005 Jul 4;202(1):135-43
references.pmid: 15998792
references.citation: Ann N Y Acad Sci. 2008 Nov;1143:1-20
references.pmid: 19076341
references.citation: Nat Immunol. 2004 Dec;5(12):1219-26
references.pmid: 15549123
references.citation: J Immunol. 2001 Mar 1;166(5):2961-9
references.pmid: 11207245
references.citation: Annu Rev Immunol. 2005;23:275-306
references.pmid: 15771572
references.citation: Front Biosci. 2008 May 01;13:6034-42
references.pmid: 18508640
references.citation: Rheumatology (Oxford). 2003 Apr;42(4):563-9
references.pmid: 12649404
references.citation: Blood. 2000 Oct 1;96(7):2537-42
references.pmid: 11001908
references.citation: J Immunol. 2003 Mar 15;170(6):3059-64
references.pmid: 12626561
references.citation: J Exp Med. 2002 Jun 3;195(11):1507-12
references.pmid: 12045249
references.citation: Nature. 2005 Apr 21;434(7036):1035-40
references.pmid: 15815647
references.citation: Oncogene. 2007 Feb 22;26(8):1166-77
references.pmid: 16924235
references.citation: Arthritis Rheum. 2007 Jul;56(7):2255-66
references.pmid: 17599748
references.citation: Blood. 2006 Mar 15;107(6):2423-31
references.pmid: 16293610
references.citation: Arthritis Rheum. 1997 Sep;40(9):1725
references.pmid: 9324032
references.citation: Nat Immunol. 2007 May;8(5):487-96
references.pmid: 17417641
references.citation: Science. 2003 May 16;300(5622):1148-51
references.pmid: 12702806
references.citation: Cancer Res. 2009 Mar 15;69(6):2416-24
references.pmid: 19276383
references.citation: J Exp Med. 2008 Feb 18;205(2):315-22
references.pmid: 18227218
references.citation: Nat Immunol. 2004 Oct;5(10):1061-8
references.pmid: 15361868
references.citation: Science. 2001 Nov 16;294(5546):1540-3
references.pmid: 11711679
references.citation: Blood. 2002 Sep 1;100(5):1828-34
references.pmid: 12176906
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):276-81
references.pmid: 17190815
references.citation: Arthritis Rheum. 2004 Jun;50(6):1861-72
references.pmid: 15188363
references.citation: Cell Biol Int. 2008 Aug;32(8):1006-13
references.pmid: 18579417
references.citation: Arthritis Rheum. 2006 Jun;54(6):1906-16
references.pmid: 16736505
references.citation: J Exp Med. 2006 Jul 10;203(7):1795-803
references.pmid: 16785313
references.citation: Lupus. 2008 May;17(5):394-9
references.pmid: 18490415
references.citation: Nature. 2005 Apr 7;434(7034):772-7
references.pmid: 15800576
references.citation: Arthritis Res Ther. 2008;10(2):R29
references.pmid: 18321389
references.citation: J Immunol. 2006 Oct 1;177(7):4841-52
references.pmid: 16982926